According to the company, the system minimizes GMP plasmid cost, process complexity, and supply chain risk by integrating viral genes into the host cell.
This enables lentiviral production from a single-plasmid transfection, in contrast to the standard four-plasmid process.
Alec Nielsen, CEO and co-founder of Asimov, said: “We’re excited to announce the launch of LV Edge, a significant leap toward solving the challenges of lentiviral manufacturing.
“By marrying mammalian synthetic biology, cutting-edge predictive models, and flexible computer-aided design software, the LV Edge Packaging System is the first of multiple planned offerings to enable cell and gene therapy developers.
“Later this year, we will expand the LV Edge offering with a fully stable lentiviral producer cell line development service, unlocking even greater scalability and cost reduction. This system builds on the success of our CHO Edge system for advanced antibody production, deepening our commitment to democratize the state of the art in genetic design capabilities to our partners.”
In addition, the system has high harvest titers of over 1E8 TU/mL across multiple chimeric antigen receptor (CAR) transgenes and enables tuneable transgene expression in the transduced cell.
